Seema Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seema Singh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Pratap Singh
Department of Cell and Molecular Biology University of Mississippi Medical Center Jackson Mississippi USA
24 shared publications - Kunwar Somesh Vikramdeo
Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
21 shared publications - Shashi Anand
Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS, USA; Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA
21 shared publications - Santanu Dasgupta
Department of Pathology, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL 36617, USA
20 shared publications - James Elliot Carter
Department of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama
19 shared publications - Mary Oluwadamilola Haastrup
Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama
19 shared publications
Latest Publications
- 13 April 2026
- Published by Wiley in The Prostate
- Vol. 86 (7)
Cover Image: Volume 86 Issue 7
- 10 February 2026
- Published by Wiley in The Prostate
- Vol. 86 (7) , 753-762
Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes
Background: Smoking is a modifiable risk factor for prostate cancer (PCa) diagnosis, recurrence, and mortality. While the mutagenic effects of tobacco are well‐documented, the immunological consequences of smoking within the tumor microenvironment (TME) are poorly understood. This study investigates how smoking reshapes the PCa immune landscape and how the associated changes could potentially be associated with patient survival. Methods: Tumor tissues from smoker and nonsmoker prostate cancer patients were subjected to multiplex gene expression analysis of immune cell types using the nanoString nCounter® PanCancer immune profiling panel to examine the effect of smoking behavior on the immune landscape. Gene expression data were also analyzed using Enrichr to identify differentially activated pathways in smoker versus nonsmoker patients. Further, we surveyed public databases to examine the association between top differentially‐expressed genes and altered immune cell abundance with patient survival. Results: Current‐smokers exhibited significantly higher infiltration of tumor‐associated macrophages (TAMs) ( p = 0.036) and regulatory T cells (Tregs) ( p = 0.045), compared to nonsmokers, with a trend for lower mast cell infiltration ( p = 0.055). A significant positive correlation ( r = 0.42; p = 0.036) was observed between TAMs with Tregs in all samples, with a stronger correlation in current‐smokers ( r = 0.88; p = 0.008) than nonsmokers ( r = 0.26; p = 0.403). A total of 89 DEGs were identified between current‐smokers and nonsmokers, associated with upregulation of immunosuppressive pathways including “primary immunodeficiency” and “PD‐L1 expression and PD‐1 checkpoint,” and downregulation of “antigen‐processing and ‐presentation” and “NF‐kappa‐B signaling” pathways. Key upregulated genes, MAGEA3, POU2AF1, and SEMG1, correlated with immune suppression markers and poorer PCa patient survival. Concomitant high TAM and Treg infiltration also significantly correlated with reduced overall survival ( p = 0.04). No significant differences were observed between current‐smokers and former‐smokers, who exhibited patterns similar to nonsmokers. Conclusions: These findings suggest that active smoking creates an immunosuppressive TME, potentially facilitating rapid tumor growth and aggressive progression. Smoking cessation may reverse these changes, highlighting the clinical significance of smoking behavior in disease outcomes.
- 10 February 2026
- Published by Wiley in The Prostate
- Vol. 86 (7) , 753-762
Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes
Background: Smoking is a modifiable risk factor for prostate cancer (PCa) diagnosis, recurrence, and mortality. While the mutagenic effects of tobacco are well‐documented, the immunological consequences of smoking within the tumor microenvironment (TME) are poorly understood. This study investigates how smoking reshapes the PCa immune landscape and how the associated changes could potentially be associated with patient survival. Methods: Tumor tissues from smoker and nonsmoker prostate cancer patients were subjected to multiplex gene expression analysis of immune cell types using the nanoString nCounter® PanCancer immune profiling panel to examine the effect of smoking behavior on the immune landscape. Gene expression data were also analyzed using Enrichr to identify differentially activated pathways in smoker versus nonsmoker patients. Further, we surveyed public databases to examine the association between top differentially‐expressed genes and altered immune cell abundance with patient survival. Results: Current‐smokers exhibited significantly higher infiltration of tumor‐associated macrophages (TAMs) ( p = 0.036) and regulatory T cells (Tregs) ( p = 0.045), compared to nonsmokers, with a trend for lower mast cell infiltration ( p = 0.055). A significant positive correlation ( r = 0.42; p = 0.036) was observed between TAMs with Tregs in all samples, with a stronger correlation in current‐smokers ( r = 0.88; p = 0.008) than nonsmokers ( r = 0.26; p = 0.403). A total of 89 DEGs were identified between current‐smokers and nonsmokers, associated with upregulation of immunosuppressive pathways including “primary immunodeficiency” and “PD‐L1 expression and PD‐1 checkpoint,” and downregulation of “antigen‐processing and ‐presentation” and “NF‐kappa‐B signaling” pathways. Key upregulated genes, MAGEA3, POU2AF1, and SEMG1, correlated with immune suppression markers and poorer PCa patient survival. Concomitant high TAM and Treg infiltration also significantly correlated with reduced overall survival ( p = 0.04). No significant differences were observed between current‐smokers and former‐smokers, who exhibited patterns similar to nonsmokers. Conclusions: These findings suggest that active smoking creates an immunosuppressive TME, potentially facilitating rapid tumor growth and aggressive progression. Smoking cessation may reverse these changes, highlighting the clinical significance of smoking behavior in disease outcomes.
- Open Access
- 16 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217916
MYB and HIF1α crosstalk drives hypoxia-induced transcriptional reprogramming and adaptive signaling alterations in pancreatic cancer
- 16 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 631, 217916
Open AccessMYB and HIF1α crosstalk drives hypoxia-induced transcriptional reprogramming and adaptive signaling alterations in pancreatic cancer
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure 5 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 5 and its figure legend
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 5 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 5 and its figure legend
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 1 and its figure legend
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 1 and its figure legend
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary table 1
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary table 1
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure 2 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 2 and its figure legend
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 2 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 2 and its figure legend
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary table 1
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary table 1
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure 3 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 3 and its figure legend
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 3 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 3 and its figure legend
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary figure 3 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 3 and its figure legend
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 3 from Mitochondrial Translocase TOMM22 Is Overexpressed in Pancreatic Cancer and Promotes Aggressive Growth by Modulating Mitochondrial Protein Import and Function
This file contains supplementary figure 3 and its figure legend